Tobin Schilke - 30 Jun 2021 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Gordon Ho, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
30 Jun 2021
Net transactions value
+$10,744
Form type
4
Filing time
02 Jul 2021, 19:53:56 UTC
Next filing
17 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Other $10,744 +446 +0.65% $24.09 69,208 30 Jun 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).